QureBio Ltd. Introduces Clinical Insights on Q-1802
QureBio Ltd. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies, particularly bispecific antibodies designed to combat severe health conditions such as cancer and inflammation. Recently, the company made headlines by announcing the presentation of Phase II clinical data for its Q-1802 program at the forthcoming SITC 39th Annual Meeting. This significant event is set to take place in the near future.
What is Q-1802?
Q-1802 stands out as the first FDA-approved bispecific antibody targeting Claudin18.2 and PD-L1. This innovative humanized antibody harnesses multiple immune mechanisms, enabling it to attack tumor cells effectively via pathways like antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). Such mechanisms represent a promising therapeutic approach for patients exhibiting Claudin18.2 positive solid tumors.
Phase II Clinical Data Presentation
During the SITC meeting, insights regarding the efficacy and safety of Q-1802 will be disclosed. Preliminary Phase II results revealed that out of 20 patients in the 10 mg/kg dosing group, an impressive objective response rate (ORR) of 70.0% was observed. Notably, the safety profile of Q-1802 also appears strong, as adverse events classified as Grade 3 or higher were reported in only about 55% of participants, with no related fatalities.
Key Findings from the Clinical Trial
- Q-1802 effectively targets the Claudin18 isoform 2 (CLDN18.2) present in tumor cells as well as the immune checkpoint PD-L1.
- The overall objective response among treated individuals was recorded at approximately 70.0% in the 10 mg/kg cohort.
- The trial indicated a 55% occurrence of Grade 3 or higher adverse reactions, demonstrating a commendable safety profile with no fatalities linked to the drug.
- Clinical observations confirmed that Q-1802 exhibits considerable anti-tumor activity.
Company Background: Innovation at QureBio Ltd.
Founded by a dedicated team of scientists in 2017 with initial funding from Viva Bio-Innovator, QureBio Ltd. is committed to addressing urgent clinical needs. Their cutting-edge research focuses on developing biopharmaceuticals with a focus on bispecific and tri-specific antibodies that can significantly improve the treatment landscape for conditions like refractory cancers and inflammatory diseases.
To date, the company has garnered support from a range of investors, including Jundu Investment and Watson Capital, resulting in significant funding rounds that total nearly 200 million CNY in Series-B financing.
Collaborations and Future Directions
QureBio Ltd. places great emphasis on collaborative projects, partnering with various industry leaders like BRL Medicine, Precision Scientific, and Hengrui Pharmaceuticals, which enhances their capacity to develop novel therapeutics aimed at tackling pressing medical challenges.
Contact Information
For additional inquiries, QureBio Ltd. can be reached directly:
Phone: +86 21-61622561
Website: www.qurebio.com
Address: 1227 Zhangheng Road, Building 1, Room 206, Pudong New Area, Shanghai, 201203
Frequently Asked Questions
What is the focus of QureBio Ltd.?
QureBio Ltd. focuses on developing biopharmaceuticals, particularly innovative bispecific antibodies, for serious health issues like cancer and inflammation.
What significant data will QureBio present?
The company will unveil Phase II clinical data for its bispecific antibody Q-1802, showcasing its efficacy and safety profile.
What are the expected outcomes from the clinical data presented?
The data is anticipated to demonstrate a strong objective response rate and a favorable safety profile among patients treated with Q-1802.
When and where will the presentation take place?
The data will be presented at the SITC 39th Annual Meeting, an important gathering for professionals in the field of immunotherapy.
How does Q-1802 work?
Q-1802 targets both Claudin18.2 and PD-L1, employing immune mechanisms such as ADCC and ADCP to effectively attack and eliminate tumor cells.
